



9th ANNUAL (VIRTUAL) MEETING OF THE LUPUS ACADEMY

Meeting Book

11 – 13th September, 2020



Welcome

Dear Friends and Colleagues,

We are delighted to welcome you to the 9th Annual Meeting of The Lupus Academy[†] and hope you will find it a rich, engaging, informative and rewarding environment in which you can develop both your knowledge of and your practical abilities for managing lupus.

The Lupus Academy is committed to continuing the development of high-quality educational programmes, focused on providing insightful and clinically relevant content through both live meetings and eLearning environments. With this, we aim to support you as you strive to provide optimal patient care and improve patient outcomes in lupus.

This Virtual Annual Meeting aims to provide latest insights into advances in global research and clinical practice in lupus and allied diseases. Delegate feedback from our previous annual meetings continues to guide us in selecting the topics and speakers you need to ensure translation of treatment advances into your clinical practice. This meeting has been approved for *AMA PRA Category 1 Credit*[™].

The scientific component of this programme, developed by our Steering Committee of 12 international experts in lupus, is designed to create a highly interactive forum through which we can all develop a logical approach to the management of lupus worldwide. This virtual meeting will give you the opportunity to engage with like-minded clinicians and scientists, share clinical and scientific experience, and continue to develop your knowledge in this fast-moving therapeutic area.

We sincerely hope that this meeting will provide you with new ideas for your clinical work, enriched enthusiasm for collaborative research, and fruitful discussions with your colleagues who care for patients with lupus.

We look forward to meeting and talking with you online, September 11–13th, 2020 .

With kind regards,

Professor Andrea Doria
Lupus Academy co-Chair (2020)

Professor Ronald van Vollenhoven
Lupus Academy co-Chair (2020)

Professor Zahir Amoura
Professor Richard Furie
Professor Sandra Navarra

Professor Eloisa Bonfá
Professor Bevra Hahn
Professor Murray Urowitz

Professor Ricard Cervera
Professor David Isenberg

Professor Thomas Dörner
Professor Bernardo Pons-Estel

[†]The Lupus Academy is a long-term initiative dedicated to improving patient outcomes in SLE through an interactive educational forum dedicated to sharing best clinical practice through the dissemination and discussion of clinical and basic scientific research about SLE and allied diseases.



Meeting Learning Objectives

The 9th Annual Meeting programme of the Lupus Academy will focus on current key issues in lupus clinical practice and is designed to facilitate improved understanding of these issues and their management through both didactic lectures and shared clinical insights through case study workshops. At the end of the programme delegates should be able to:

- Describe current and future treatment options for optimising the management of SLE
- Explain and debate the role of IFN signature as a reliable biomarker and IFN inhibition as a viable treatment approach in SLE
- Discuss novel approaches in the management of SLE, including measurement of disease activity, self-care for patients with lupus, and biologics and pregnancy
- Demonstrate optimal assessment and monitoring of patients with SLE
- Discuss cases of different lupus manifestations, their comorbidities and management of these in clinical practice, including dermatological, cardiovascular, kidney disease in pregnancy and rare disease manifestations
- Demonstrate understanding of targeting novel treatment pathways and their effect on clinical outcomes, including low-dose interleukin 2, 12 and 23, plasma cells and novel intracellular pathways
- Describe treat-to-target and low disease activity and their application in clinical practice with available novel therapies
- Discuss the definition and treatment approaches for refractory lupus manifestations, including nephritis, cytopenias, musculoskeletal involvement and APS in SLE

Abstracts of the presentations are published in the official journal of the 9th Annual Meeting:



Continuing Medical Education



This meeting has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and the Lupus Academy. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians.

Siyemi Learning designates this live activity for a maximum of 16 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information on how to claim CME credits can be found on the meeting website. The CME credits are recognised across Europe and globally. Please check with your local authority to confirm its validity for your purposes.

Disclosures

Financial disclosures of the speakers can be found with their biography in this book.

Neither the Lupus Academy planning staff, Julian Ball, Nicole Elzebroek, Eugene Pozniak, nor staff at Siyemi Learning, have any relevant financial relationships to disclose.

Further information about Lupus Academy, partners and sponsors can be found on Page 26 of this book.

Contents

| | |
|--------------------------|-----------|
| Programme | 4 |
| Biographies | 10 |
| Notes | 28 |



Programme

Friday 11th September 2020

OPENING SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00 – 15:15 hours
EDT (UTC-4 New York, Montreal, Lima) 7:00 AM – 9:15 AM
CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:15 hours

| | |
|--|--|
| Opening | <i>Andrea Doria (Italy)</i> <i>Ronald van Vollenhoven (Netherlands)</i> |
| Keynote | <i>Moderator: Andrea Doria (Italy)</i> |
| Understanding and treating SLE: A new era is dawning | <i>Ronald van Vollenhoven (Netherlands)</i> |
| Debate: New Developments in Basic Science and Clinical Research: Defining SLE | <i>Moderator: Ricard Cervera (Spain)</i> |
| The matter of the debate | <i>Ricard Cervera (Spain)</i> |
| A majority of lupus patients (will) need a biologic! | <i>David Isenberg (UK)</i> |
| A minority of lupus patients (will) need a biologic! | <i>Murray Urowitz (Canada)</i> |

PLENARY I: NEW ASPECTS IN THE MANAGEMENT OF SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30 – 17:00 hours
EDT (UTC-4 New York, Montreal, Lima) 9:30 AM – 11:00 AM
CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:00 hours

| | |
|---|-------------------------------|
| Moderators: Zahir Amoura (France), Bernardo Pons-Estel (Argentina) | |
| Measuring SLE disease activity in 2020: Perspectives from clinical research | <i>Luís Inês (Portugal)</i> |
| Lifestyle for lupus patients: exercise, diet, and well-being: Perspectives from clinical practice | <i>Chiara Tani (Italy)</i> |
| Microangiopathy in SLE: A diagnostic and therapeutic challenge | <i>Ricard Cervera (Spain)</i> |
| Panel Discussion and Q&A | <i>All</i> |

PLENARY II: NOVEL THERAPEUTIC DEVELOPMENTS IN 2020

CET (UTC+2 Paris, Amsterdam, Berlin) 17:30 – 19:30 hours
EDT (UTC-4 New York, Montreal, Lima) 11:30 AM – 1:30 PM
CST (UTC+8 Beijing, Manila, Perth) 23:30 – 01:30 hours

| | |
|--|--------------------------------|
| Moderators: Richard Furie (USA), Ronald van Vollenhoven (Netherlands) | |
| Plasma-cell directed therapies | <i>Reinhard Voll (Germany)</i> |
| IL-12/23 directed therapies | <i>Bevra Hahn (USA)</i> |
| Novel intracellular pathways | <i>Thomas Dörner (Germany)</i> |
| Molecules in early development | <i>Richard Furie (USA)</i> |
| Panel Discussion and Q&A | <i>All</i> |

Saturday 12th September 2020

PLENARY II: NOVEL THERAPEUTIC DEVELOPMENTS IN 2020

(Recorded Session from Friday. Live Panel Discussion and Q&A)

CET (UTC+2 Paris, Amsterdam, Berlin) 07:30 – 09:30 hours

EDT (UTC-4 New York, Montreal, Lima) 1:30 AM – 3:30 AM

CST (UTC+8 Beijing, Manila, Perth) 13:30 – 15:30 hours

| Moderators: Richard Furie (USA), Ronald van Vollenhoven (Netherlands) | |
|--|--------------------------------|
| Plasma-cell directed therapies | <i>Reinhard Voll (Germany)</i> |
| IL-12/23 directed therapies | <i>Bevra Hahn (USA)</i> |
| Novel intracellular pathways | <i>Thomas Dörner (Germany)</i> |
| Molecules in early development stage | <i>Richard Furie (USA)</i> |
| Panel Discussion and Q&A | <i>All</i> |

FOUR HOT TOPICS (Session 1)

CET (UTC+2 Paris, Amsterdam, Berlin) 10:00 – 11:50 hours

EDT (UTC-4 New York, Montreal, Lima) 4.00 AM – 5.50 AM

CST (UTC+8 Beijing, Manila, Perth) 16:00 – 17:50 hours

| Moderator: Thomas Dörner (Germany) | |
|---|---------------------------------|
| Remission and low disease activity: the new targets for treatment | <i>George Bertsias (Greece)</i> |
| Belimumab helps lupus patients to achieve lupus targets | <i>Andrea Doria (Italy)</i> |
| Can we withdraw low-dose prednisone in remitted patients? | <i>Zahir Amoura (France)</i> |
| Can we withdraw immunosuppressants in remitted patients? | <i>Margherita Zen (Italy)</i> |
| Panel Discussion and Q&A | <i>All</i> |

CASE STUDY INTERACTIVE WORKSHOPS (Session 1)

CET (UTC+2 Paris, Amsterdam, Berlin) 12:00–13:30 hours

EDT (UTC-4 New York, Montreal, Lima) 6:00 AM – 7:30 AM

CST (UTC+8 Beijing, Manila, Perth) 18:00 – 19:30 hours

| Moderator/Facilitator: Andrea Doria (Italy) | |
|---|--|
| Management of refractory skin lupus | <i>Annegret Kuhn (Germany), Marzia Caproni (Italy)</i> |
| Moderator/Facilitator: Bernardo Pons-Estel (Argentina) | |
| Management of cardiovascular risk in SLE | <i>Murray Urowitz (Canada), Eloisa Bonfá (Brazil)</i> |
| Moderator/Facilitator: Sandra Navarra (Philippines) | |
| Fertility and pregnancy issues in patients with lupus nephritis | <i>Angela Tincani (Italy), Liz Lightstone (UK)</i> |
| Moderator/Facilitator: David Isenberg (UK) | |
| Rare disease manifestations in SLE | <i>Zahir Amoura (France), Richard Furie (USA)</i> |

Programme

Saturday 12th September 2020 *continued*

PRIME TIME SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:30 – 15:00 hours
EDT (UTC-4 New York, Montreal, Lima) 7:30 AM – 9:00 AM
CST (UTC+8 Beijing, Manila, Perth) 19.30 – 21:00 hours

Hot Topic

Moderators: Murray Urowitz (Canada), David Isenberg (UK)

Optimal assessment and monitoring of SLE patients in clinical practice

Alexandre Voskuyl (Netherlands)

State-of-the-art

Moderators: Bevra Hahn (USA), Sandra Navarra (Philippines)

Diagnosis and treatment of neuropsychiatric lupus

Marcello Govoni (Italy)

Covid-19 and SLE – What do we know today?

Fabrizio Conti (Italy)

CASE STUDY INTERACTIVE WORKSHOPS (Session 2)

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30 – 17:00 hours
EDT (UTC-4 New York, Montreal, Lima) 9:30 AM – 11:00 AM
CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:00 hours

Moderator/Facilitator: Andrea Doria (Italy)

Management of refractory skin lupus

*Annegret Kuhn (Germany),
Marzia Caproni (Italy)*

Moderator/Facilitator: Bernardo Pons-Estel (Argentina)

Management of cardiovascular risk in SLE

*Murray Urowitz (Canada),
Eloisa Bonfá (Brazil)*

Moderator/Facilitator: Sandra Navarra (Philippines)

Fertility and pregnancy issues in patients with lupus nephritis

*Angela Tincani (Italy),
Liz Lightstone (UK)*

Moderator/Facilitator: David Isenberg (UK)

Rare disease manifestations in SLE

*Zahir Amoura (France),
Richard Furie (USA)*

FOUR HOT TOPICS (Session 2)

CET (UTC+2 Paris, Amsterdam, Berlin) 17:30 – 19:40 hours
EDT (UTC-4 New York, Montreal, Lima) 11:30 AM – 1:40 PM
CST (UTC+8 Beijing, Manila, Perth) 23:30 – 01:40 hours

Moderator: Thomas Dörner (Germany)

Remission and low disease activity: the new targets for treatment

George Bertias (Greece)

Belimumab helps lupus patients to achieve lupus targets

Andrea Doria (Italy)

Can we withdraw low-dose prednisone in remitted patients?

Zahir Amoura (France)

Can we withdraw immunosuppressants in remitted patients?

Margherita Zen (Italy)

Panel Discussion and Q&A

All

Sunday 13th September 2020

PRE-RECORDED SESSION*

CET (UTC+2 Paris, Amsterdam, Berlin) 07:00 – 10:50 hours
 EDT (UTC+4 New York, Montreal, Lima) 1:00 AM – 4:50 AM
 CST (UTC+8 Beijing, Manila, Perth) 13:00 – 16:50 hours


| Keynote | |
|---|---|
| Moderator: Andrea Doria (Italy) | |
| Understanding and treating SLE: A new era is dawning Recorded Q&A (15 Mins) | <i>Ronald van Vollenhoven (Netherlands)</i> |
| Debate: New Developments in Basic Science and Clinical Research: Defining SLE | |
| Moderator: Ricard Cervera (Spain) | |
| The matter of the debate | <i>Ricard Cervera (Spain)</i> |
| A majority of lupus patients (will) need a biologic! | <i>David Isenberg (UK)</i> |
| A minority of lupus patients (will) need a biologic! | <i>Murray Urowitz (Canada)</i> |
| Recorded Voting, Q&A and Discussion (20 Mins) | <i>All</i> |
| Hot Topic | |
| Moderators: Murray Urowitz (Canada), David Isenberg (UK) | |
| Optimal assessment and monitoring of SLE patients in clinical practice Recorded Q&A (10 Mins) | <i>Alexandre Voskuyl (Netherlands)</i> |
| State-of-the-art | |
| Moderators: Bevra Hahn (USA), Sandra Navarra (Philippines) | |
| Diagnosis and treatment of neuropsychiatric lupus Q&A (10 Mins) | <i>Marcello Govoni (Italy)</i> |
| Covid-19 and SLE – What do we know today? Q&A (10 Mins) | <i>Fabrizio Conti (Italy)</i> |

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

MEET THE EDITOR

CET (UTC+2 Paris, Amsterdam, Berlin) 11:00 – 11:55 hours
 EDT (UTC+4 New York, Montreal, Lima) 5:00 AM – 5:55 AM
 CST (UTC+8 Beijing, Manila, Perth) 17:00 – 17:55 hours

| Moderator: Ronald van Vollenhoven (Netherlands) | |
|--|---|
| Introduction: What is happening in the world of publishing? | <i>Ronald van Vollenhoven (Netherlands)</i> |
| Workshop: How do I get my manuscript published—in the best possible journal? | |
| Tips for reviewers: make it work for the authors and yourself | |



Programme

Sunday 13th September 2020 *continued*

POSTER SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 12:00 – 12:50 hours
EDT (UTC+4 New York, Montreal, Lima) 6:00 AM – 6:50 AM
CST (UTC+8 Beijing, Manila, Perth) 18:00 – 18:50 hours

Poster

Moderators: Ronald van Vollenhoven (Netherlands)/Andrea Doria (Italy)

Posters: Lupus Academy Commendation
Five Poster Presentations*: (5 minutes each)

Q&A (5 minutes each poster)

*More Posters Available Online

ROUNDTABLE: REFRACTORY LUPUS MANIFESTATIONS: DEFINITION AND TREATMENT

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00 – 15:00 hours
EDT (UTC+4 New York, Montreal, Lima) 7:00 AM – 9:00 AM
CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:00 hours

Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)

| | |
|---|--|
| Refractory lupus nephritis Q&A (10 Mins) | <i>Sandra Navarra (Philippines)</i> |
| Refractory lupus cytopenias Q&A (10 Mins) | <i>Eloisa Bonfá (Brazil)</i> |
| Refractory musculoskeletal manifestations Q&A (10 Mins) | <i>Bernardo Pons-Estel (Argentina)</i> |
| Refractory and/or catastrophic APS in SLE Q&A (10 Mins) | <i>Ricard Cervera (Spain)</i> |
| Panel Discussion and Q&A | <i>All</i> |
| Close | <i>Andrea Doria (Italy) Ronald van Vollenhoven (Netherlands)</i> |

Biographies



Professor Zahir Amoura, MD, MSc

French National Reference Center for SLE and APS, Pitié-Salpêtrière Hospital, Paris, France

Zahir Amoura is Professor of Internal Medicine at the French National Reference Center for Systemic Lupus Erythematosus at Pitié-Salpêtrière Hospital, a role that he has held since 2003. In 2009, Professor Amoura became Head of the Department of Internal Medicine 2 in the same institution. Professor Amoura completed his Paris Hospital Medical Internship in 1988, and obtained a Master's degree in Immunopharmacology in 1989. He was subsequently awarded his MD (silver medal) in 1993 and his qualifying certification in internal medicine in 1994. Professor Amoura joined the Department of Internal Medicine at Pitié-Salpêtrière Hospital in 1995 as a Senior Lecturer and Senior Practitioner. Professor Amoura has published over 513 peer-reviewed papers, of which 220 focused on the immunopathological features of lupus.

Professor Amoura is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Grants/Research: Amgen; AstraZeneca; GSK; Roche

Consultant/Advisor: AstraZeneca; GSK



Professor George Bertsias, MD, PhD

University of Crete School of Medicine, Greece

George Bertsias graduated from the University of Crete School of Medicine (UoCSM) in 2002. After his internship, he pursued graduate studies and received his M.Sc. degree in 2006 and Ph.D. in immunology/autoimmunity in 2009. He has performed post-doctoral research in the laboratory of Dr Daniel Kastner at the National Institute of Human Genome Research Institute, National Institutes of Health (NIH/NHGRI). Professor Bertsias is board certified in Internal Medicine and in Rheumatology.

Professor Bertsias has developed scientific interest in systemic autoimmunity and Systemic Lupus Erythematosus (SLE) and has been an active member of the EULAR study group on SLE, where he has coordinated the preparation of a number of clinical recommendations for the diagnosis and treatment of patients with SLE, including lupus nephritis, neuropsychiatric lupus and management of pregnancy in women with SLE. He is a EULAR-accredited clinical methodologist.

In 2014, he was appointed Lecturer in Rheumatology-Clinical Immunology and Principal Investigator at the Laboratory of Autoimmunity and Inflammation, UoCSM. His research focuses on immune regulation by costimulatory receptors, inflammatory cytokines (e.g. IL-33) and cellular metabolic pathways using SLE as a disease-model and by applying high-throughput technologies in patient tissues. In addition, Professor Bertsias has organized and runs a dedicated Connective Tissue Diseases (CTDs) / SLE clinic that serves as referral center for the island of Crete and Southern Aegean region. He also manages the Cretan Lupus Registry, which has registered more than 700 SLE patients with complete sociodemographic and clinical characteristics. Professor Bertsias has established collaborations with other research groups in Europe and the US and has actively participated and supervised several projects related to diagnostic and therapeutic aspects of SLE. In July 2016, he was promoted to Assistant Professor (UoCSM). He has published more than 100 peer-reviewed papers (PubMed) and several textbook chapters pertinent to SLE.

Financial Disclosures

None



Professor Eloisa Bonfá, MD, PhD
University of São Paulo Medical School, São Paulo, Brazil

Eloisa Bonfá is the Physician-in-Chief of the Rheumatology Division of Hospital das Clinicas HCFMUSP, São Paulo, which is the largest tertiary referral centre for autoimmune rheumatic disorders of Latin America. She is now in her third term elected Clinical Director of Hospital das Clinicas HCFMUSP, University of Sao Paulo.

Professor Bonfá's main clinical and research interest is systemic lupus erythematosus and autoimmunity, with relevant contribution in the field of autoantibodies and original contribution regarding the association of anti-ribosomal P antibodies with psychiatric manifestation of lupus and the first "in vitro" demonstration of the arrhythmogenic potential of purified Ro/ SSA antibodies. She also has described the association of anti-ribosomal P antibodies and lupus membranous nephritis. She has published several papers on vaccine immunogenicity and safety in autoimmune disorders. More recently, she has been dedicated to monitoring hydroxychloroquine blood levels in lupus patients.

Having graduated at the University of São Paulo Medical School, Brazil, Professor Bonfá undertook specialist training in Rheumatology in the same University followed by a 4 year rheumatology research fellowship at the Hospital for Special Surgery, New York, USA, under the supervision of Professor Keith Elkon. She has published more than 300 original papers indexed in PubMed and several book chapters.

Professor Bonfá is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures
None



Dr Marzia Caproni MD, PhD
University of Florence, Italy

Marzia Caproni is the Director of Skin Immunopathology and Rare Dermatological Disease Unit at P.O. Piero Palagi, USL Toscana Centro of Florence, University of Florence, Italy. She is the Coordinator for Tuscan Region of Rare Skin Diseases.

Dr Caproni received her medical degree and qualification in Dermatology and Venereology from the University of Pisa and qualification in Allergy and Clinical Immunology from the University of Florence. She obtained her PhD in Experimental Dermatology at the University of Naples and became Associate Professor at the School of Specialization in Dermatology, University of Florence in 1997.

From 2004 to 2010 Dr Caproni has been Coordinator of the Italian group for Cutaneous Immunopathology of the Italian Society of Dermatology (SIDEMAST), organising specific national meetings and research projects, some of them with national financing.

Dr Caproni is now a member of two task forces of the European Academy of dermatology and Venerology (EADV) on lupus erythematosus and cutaneous vasculitis. She contributed to the development of the guidelines for diagnosis, management and monitoring of cutaneous lupus erythematosus and of the addendum for naming and classification of cutaneous vasculitis.

Dr Caproni is author of several publications on lupus and other connective tissue diseases. She has a long-standing experience of the clinical management of patients with connective tissue diseases.

Financial Disclosures
None

Biographies



Professor Ricard Cervera, MD, PhD, FRCP Hospital Clinic, Barcelona, Catalonia, Spain

Ricard Cervera is co-Founder and Head of the Department of Autoimmune Diseases at Hospital Clinic, Barcelona. He is also leader of the Research Team on Systemic Autoimmune Diseases at the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Professor at the University of Barcelona where he coordinates the Masters Course on Autoimmune Diseases and serves as Vice-Dean of Academic Affairs and International Relations at its Faculty of Medicine and Health Sciences. He qualified in medicine in 1983 from the University of Barcelona and received his PhD in 1988 for his thesis on anticardiolipin antibodies. He spent 2 years at the Lupus Research Unit at The Rayne Institute, St Thomas' Hospital, London, UK.

Professor Cervera is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures
None

Professor Cervera is an Associate Editor of the journal *Lupus Science & Medicine* and is on the Editorial Boards of 20 medical journals. He is Founder and Member of the Board of the European Lupus Society and past-coordinator of the European Working Party on Systemic Lupus Erythematosus (Euro-Lupus Group) (1991–2008) and of the European Forum on Antiphospholipid Antibodies (2009–2017). He is Chairman of the Medical Advisory Board of the Catalan Association of Lupus Patients and Medical Advisor to Lupus Europe. He chaired the 6th, 8th and 11th International Congresses on Autoimmunity, the 1st, 2nd and 5th Latin-American Congresses on Autoimmunity, the 5th Meeting of the European Forum on Antiphospholipid Antibodies and the 8th European Lupus Congress.

Professor Cervera's research interests include clinical and epidemiological aspects of systemic autoimmune diseases, particularly SLE and antiphospholipid syndrome, with special focus on its 'catastrophic' variant. He has presented over 300 invited lectures and published more than 800 scientific papers (H-Index, 79), including original articles in the *New England Journal of Medicine*, *The Lancet*, *Annals of Rheumatic Diseases*, *Arthritis & Rheumatism*, *American Journal of Medicine* and *Medicine (Baltimore)*. He is co-Editor of 25 books, including 'The Antiphospholipid Syndrome', 'Vascular Manifestations of Systemic Autoimmune Diseases' and 'Diagnostic Criteria in Autoimmune Diseases'.



Professor Fabrizio Conti Sapienza University of Rome, Italy

Fabrizio Conti is Professor of Rheumatology, Head of Rheumatology Unit and Director of the post-graduate School of Rheumatology, at Sapienza University of Rome, Italy. He obtained PhD qualification in Experimental Immunology from the Magna Graecia University of Catanzaro, Italy. He was Council member of the Italian Society of Rheumatology (SIR) from 2012 to 2016. He is also one of the three members of the Standing Committee for the study of biological treatments in systemic lupus erythematosus (SLE) (LIRE) of SIR, a member of the Standing Committee for the study of neuropsychiatric lupus of SIR, and a member of the Standing Committee for the study of Antiphospholipid Syndrome (APS) of SIR.

Financial Disclosures
None

Professor Conti has authored over 200 ISI publications on SLE and other rheumatic diseases. He focused his research on etiopathogenesis, clinical features and treatment of SLE, APS, rheumatoid arthritis and other autoimmune rheumatic diseases. He was principal investigator in several clinical studies (phase II and III) carried out using new biological products. He has organised several congresses on autoimmune rheumatic diseases.

Professor Conti has gained wide experience in clinical management of patients with autoimmune rheumatic diseases including paediatric patients with juvenile idiopathic arthritis. In 2008 he established the "Sapienza Lupus Clinic" in which, currently, more than 1000 SLE out-patients are followed-up.



Professor Andrea Doria, MD

University of Padova, Italy

Andrea Doria is Professor of Rheumatology and Head of the Rheumatology Unit and Unit of Connective Tissue Disease and Rare Rheumatic Diseases, Department of Medicine, University of Padua, Italy.

Professor Doria received his medical degree and qualification in Rheumatology from the University of Padua. He was Council member of the Italian College of Rheumatology (CRO) between 1999 and 2005 and a Council member of the Italian Society of Rheumatology (SIR) from 2007 to 2010 and from 2013 to present. He is also a member of American College of Rheumatology (ACR).

Professor Doria has organised over ten international conferences on autoimmunity and was involved as “expert” in the European League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations: (1) EULAR recommendations for the management of systemic lupus erythematosus (SLE)—Assessment of the SLE patient (2008–2009); (2) EULAR recommendations for the management of SLE Part II—Neuropsychiatric disease (2008–2009); (3) Joint EULAR and European Renal Association- European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012). Professor Doria is a member of the Lupus Academy Steering Committee and co- Chaired the Steering Committee in 2015 and 2020. He was the Chair of the 10th European Lupus Meeting, held in Venice (Italy) 5–8th October 2016.

Professor Doria is on the Editorial Boards of several rheumatology and immunology journals, including *Lupus*, *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews*, *Journal of Autoimmunity*, *Experimental Biology and Medicine*, *Rheumatology Reports*, *Journal Autoimmunity Highlights* and *Reumatismo* (the official Journal of Italian Society of Rheumatology).

He has authored over 300 ISI publications on SLE and other connective tissue diseases. These include clinical studies describing new manifestations or subgroups of autoimmune disorders, prognostic risk factors, diagnostic tests and therapeutic interventions, as well as immunochemical studies that evaluate autoantibodies, epitopes and complementary epitopes of autoantigens. In addition, he has authored and co-authored three books, over 90 book chapters and conference proceedings, and over 700 abstracts for national and international conferences.

Professor Doria has long-standing experience of the clinical management of patients with connective tissue diseases. The unit in which he works is a tertiary referral rheumatology centre within Italy, for the diagnosis and management of patients affected with systemic connective diseases. In addition, he has expertise in the management and follow-up of pregnant patients with systemic rheumatic diseases. Professor Doria has also trained over 30 students in Rheumatology.

Professor Doria is a member of the Lupus Academy Steering Committee and as Chairman (2020) has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Consultant/Advisor: Pfizer
Speakers' Bureau: Eli Lilly;
GSK

Biographies



Professor Thomas Dörner, MD Charite University Hospitals Berlin, Germany

Thomas Dörner is a board-certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charite University Hospitals, Berlin, and group leader at the German Research Center of Rheumatology, Berlin (DRFZ). He qualified in medicine in 1990 at Charite University Hospitals, Berlin, and received his board certification in internal medicine in 1995 before undertaking a postdoctoral fellowship at the University of Texas, Southwestern Medical Center in Dallas, where he researched delineating molecular aspects of B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has received a number of international and national awards, including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, the Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases, Global Arthritis Research Network (GARN), Current Reviews in Rheumatology, the Brazilian Journal of Rheumatology, the European Journal of Immunology, Lupus Science & Medicine, and Rheumatology Reviews.

Professor Dörner has led various clinical trials on rheumatic diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue (lupus, neonatal lupus syndromes, Sjogren's syndrome), exploring innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.

Professor Dörner is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Grants/Research: Celgene; Eli Lilly; Janssen; Novartis; Roche; Sanofi-Aventis; UCB

Consultant/Advisor: Eli Lilly; Janssen; Novartis; Roche; UCB



Professor Richard Furie Zucker School of Medicine at Hofstra/Northwell, New York, USA

Professor Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System's clinical research program in musculoskeletal disease. He also directs the Hospital's systemic lupus erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognised for its role in the development of new therapies for SLE.

Regarded as one of the senior rheumatologists in the New York metropolitan area, Professor Furie has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For twenty years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Professor Furie's favourite educational venue is at home with his colleagues and trainees.

Professor Furie is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Grants/Research: Biogen; BMS; Genentech/Roche; Kezar; UCB

Consultant/Advisor: Biogen; BMS; Genentech/Roche; Kezar; UCB



Professor Marcello Govoni

University of Ferrara, Italy

Marcello Govoni is Professor of Rheumatology and Head of the Rheumatology Unit and Lupus Clinic of the Department of Medical Sciences, University of Ferrara, Italy. He is Director of Specialization School of Rheumatology, University of Ferrara.

Professor Govoni received his medical degree and qualification in Rheumatology from the University of Ferrara. He was a Council member of the Italian Society of Rheumatology (SIR) from 2007 to 2012. He is also a confirmed delegate member of ESCCA on behalf of the Italian Society of Rheumatology since 2016 up to now and coordinator of the Italian Research Study Group for the Neuropsychiatric involvement of the Italian Society of Rheumatology.

Professor Govoni has organised a number of scientific meetings of national relevance held in Ferrara and is scientific promoter and coordinator of the annual Educational Course on neuropsychiatric involvement in rheumatic disease on behalf of the Italian Society of Rheumatology. He has been involved as invited speaker and chair in a number of national and international congresses and he has been involved as “expert” in the European League Against Rheumatism (EULAR) Standing Committee for the development of updated 2019 recommendations for the management of SLE.

Professor Govoni is referee for international journals such as *Lupus*, *Rheumatology*, *Clinical and Experimental Rheumatology* and on the Editorial Boards of *Clinical and Experimental Rheumatology* and *Reumatismo* (the official journal of Italian Society of Rheumatology). He has authored over 170 ISI publications on different topics in Rheumatology, mostly neuropsychiatric lupus, SLE, other connective tissue diseases and rheumatoid arthritis. One of the main fields of his research is represented by neuropsychiatric involvement in SLE with particular reference to clinical aspects, neuroimaging, diagnostic approach and attribution. In addition, he has authored and co-authored 13 monographs, 37 book chapters conference proceedings and over 450 abstracts for national and international conferences.

Professor Govoni has long-standing experience of the clinical management of patients with SLE and other connective tissue diseases. The Unit in which he works is a tertiary referral rheumatology centre, within Italy, for the diagnosis and management of patients affected with systemic connective diseases. He has also expertise in the management and follow-up of pregnant patients with systemic rheumatic diseases.

Financial Disclosures

None



Professor Bevr Hahn, MD

University of California, Los Angeles, USA

Bevr Hahn is Distinguished Professor of Medicine (Emeritus, recalled for part time work) in the Division of Rheumatology at the University of California, Los Angeles (UCLA). She received her medical degree and Rheumatology training at Johns Hopkins University School of Medicine in Baltimore, Maryland. She was Chief of Rheumatology at UCLA for 30 years.

Professor Hahn has published research in clinical investigations and basic studies of immune tolerance (including the invention of a tolerizing peptide) and T-cell biology as they apply to systemic lupus erythematosus (SLE). For these works she and her colleagues have received several awards, including the Carol-Nachman International Award for Rheumatology Research, awards from the British Society for Rheumatology and the Dutch Society for Rheumatology, the James Klinenberg Medal of the US Arthritis Foundation, an award from the Canadian Rheumatism Society, and the Gold Medal of the American College of Rheumatology (ACR). Professor Hahn was President of the ACR (1999–2000). She is co Editor, with Daniel Wallace, of the ‘Dubois’ *Lupus Erythematosus* textbook and is first author of the ACR guidelines for the management of lupus nephritis. She continues to work in clinical research devoted to the study of SLE.

Professor Hahn is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Consultant/Advisor: Aurinia, Cugene

Biographies



Financial Disclosures

None

Professor Luís Inês, MD, PhD Coimbra University Hospital Centre, Portugal

Luís Inês is Professor of Rheumatology and Head of the CHUC Lupus Clinic, at the Rheumatology Department, Coimbra University Hospital Centre (CHUC), in Portugal.

Professor Inês received his medical degree from the University of Coimbra and qualified as Rheumatology specialist at the Coimbra University Hospital. He earned his doctoral degree in Medicine from the University of Beira Interior, with research on predictors of clinical outcomes and immunological markers in patients with Systemic lupus erythematosus. As Professor of Rheumatology, he directs the Rheumatology graduate program in Medicine, at the School of Health Sciences, University of Beira Interior, Portugal. He directs the postgraduate program in Rheumatology at his hospital, that provides clinical and research training to over 20 junior doctors per year.

Professor Inês established and leads the CHUC Lupus Clinic since 2005. This is a tertiary referral centre, now following over 400 patients with SLE and integrating multidisciplinary care. He has extensive experience on the clinical management of patients with SLE and other connective tissue diseases. In addition, he runs a multidisciplinary pregnancy clinic dedicated to the management and follow-up of pregnant patients with inflammatory rheumatic diseases.

Professor Inês is Principal Investigator of the CHUC Lupus Cohort, a long-term prospective cohort study of outcomes and disease measures in SLE patients. Research of his group includes clinical studies on prognostic factors, outcomes, measures of lupus disease activity, disease classification, clinical trials, as well as immunological and biomarker studies. He leads the research group that derived and is developing the SLE Disease Activity Score (SLE-DAS).

Professor Inês has been General secretary of the SLEuro (European Lupus Society) since 2019.



Professor Isenberg is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Cellegene;
Eli Lilly; Genentech; GSK;
Merck/Serono; UCB

Professor David Isenberg, MD, FRCP, FA MS University College London, UK

David Isenberg is the Arthritis Research UK Diamond Jubilee Professor of Rheumatology at University College London (UCL). He graduated from St. Bartholomew's Hospital, London, in 1973, and trained in general medicine, rheumatology, neurology, psychiatry and gastroenterology, becoming a Research Fellow at UCL/The Middlesex Hospital in 1979. He was awarded his MD in 1984, based on his studies of myositis. During a year of research at Tufts University, Boston, he became interested in autoantibody structure/function and origin. He was appointed Consultant Rheumatologist in 1984, Professor in 1991 and became the arc Diamond Jubilee Chair of Rheumatology at UCL in 1996. He has fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.

Professor Isenberg is on the Editorial Boards of five journals, including the Journal of Rheumatology. He is Chair of the British Isles Lupus Assessment Group and Lupus UK's Research Committee and was Chair of the Systemic Lupus International Collaborating Clinics group (1998–2003). During the past 20 years, Professor Isenberg has undertaken many roles at Arthritis Research UK and currently sits on the Executive Board.

Professor Isenberg is past-President of the British Society for Rheumatology (2004–2006) and he chaired the Society's Biologics Register Committee for 5 years (2006–2011). Professor Isenberg was the 2010 recipient of the Evelyn V. Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment. He has authored over 550 original articles, 275 reviews/chapters and 20 books, many on topics related to lupus.

Professor Isenberg's principal clinical interests are the development of disease activity and damage assessment tools in patients with lupus. His specialist interest is autoimmune rheumatic diseases, notably systemic lupus erythematosus, Sjogren's syndrome, myositis and antiphospholipid antibody syndrome. In 2016 he became a Master of the American College of Rheumatology.



Professor Annegret Kuhn, MD, MBA
University Hospital Münster, Germany

Annegret Kuhn is Professor of Dermatology and Venerology and Head of the Executive Department of the Management Board at University Hospital Münster, Germany. Professor Kuhn acquired her medical degree and her Doctor of Medicine at the University of Düsseldorf, Germany, where she also received her German Board Certification for Dermatology and Venerology and her Qualification as University Lecturer. She has also worked in scientific institutions, such as the Max-Planck-Institute for Molecular Biomedicine, Münster, and the German Cancer Research Center, Heidelberg, Germany. Professor Kuhn has also completed the MBA Health Care Management Program at the University of Bayreuth, Germany.

Financial Disclosures

None

Professor Kuhn was Head of the Interdisciplinary Center for Clinical Trials at the University Medical Center, Mainz, Germany from 2014 to 2017. Professor Kuhn's major clinical and scientific interest is translational immunology, particularly the pathogenesis, diagnosis, and treatment of cutaneous lupus erythematosus. She has also acquired extensive knowledge and long-term experience in academic care of in-patients and out-patients with autoimmune diseases. Professor Kuhn has chaired national and international guideline subcommittees and the European Society of Cutaneous Lupus Erythematosus (EUSCLE). She has published widely in high impact journals, including more than 200 original and review articles.

Biographies



Professor Liz Lightstone, PhD, FRCP Imperial College London, UK

Liz Lightstone is Professor of Renal Medicine in the Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, College Consul (Clinical) for Imperial College and an Honorary Consultant Renal Physician in the Imperial College Healthcare NHS Trust Renal and Transplant Centre (ICHNT RTC). After graduating with a first class degree in Medical Sciences Tripos from Cambridge University, she graduated medicine with honours (proxime accessit) from the University of London in 1983 and trained in nephrology at the Royal Postgraduate Medical School and Hammersmith Hospital. Following a PhD in Immunology funded by the MRC, she won an MRC Clinician Scientist Fellowship following which she was appointed as Senior Lecturer at Imperial in 1995.

Financial Disclosures

Grants/Research Support:

Roche

Consultant/Advisor:

Achillion; Alexion; AstraZeneca; Aurinia;

GSK; Janssen; Pfizer

Meeting Honorarium:

Achillion; Alexion; GSK

Professor Lightstone has held major roles in undergraduate and postgraduate medicine at Imperial College, in particular as Director of the Academic Foundation Programme within the North West Thames Foundation School from 2009 to 2015. More recently she has been appointed Deputy Campus Director Hammersmith White City Campus and elected to the role of Faculty of Medicine College Consul (Clinical).

Having started out in basic research, Prof Lightstone's research is now focused on Lupus Nephritis, as well as Pregnancy in Women with Kidney Disease. Together with colleagues in the ICHNT RTC, she pioneered the use of steroid-minimising regimens in lupus nephritis. She was Chief Investigator on the international multicentre randomised RITUXILUP trial. She is particularly interested in developing better ways of predicting outcomes, not least by improving adherence to therapy and using an 'omics approach to analysing renal biopsies. She is a co-author on the EULAR guideline on the management of Lupus Nephritis (2012) and the more recent British Society of Rheumatology guideline on the management of lupus in adults (2017).

She is also recognised for her wider expertise in glomerulonephritis and is now the global co-chair, along with Prof Dan Cattran, of the SONG-GN initiative which aims to define core outcome criteria to be included in all studies of GN – and these outcomes are generated and evaluated by both healthcare professionals and patients. She also co-chairs, with Prof David Jayne, the UK Kidney Research Consortium Glomerulonephritis Clinical Study.

She was the inaugural National Coordinator of the UK Pregnancy and Chronic Kidney Disease Rare Disease group and pioneered the use of tacrolimus in the treatment of lupus nephritis in pregnancy and demonstrated its safety for women with lupus nephritis who are breastfeeding. She is joint author on the first Renal Association Guideline on the Pregnancy and CKD published in 2019 and has published extensively on the management and outcomes of pregnancy in women with glomerular disease, in particular lupus nephritis.

Her main clinical interests are in lupus nephritis (she jointly manages a combined renal/rheumatology lupus clinic following over 400 patients with LN) and the management of women with kidney disease in pregnancy—she established (in 1996) and runs a renal obstetric clinic and a pre-pregnancy counselling clinic & her advice is sought nationally and internationally for the management of challenging cases in these areas.



Professor Sandra V. Navarra, MD
University of Santo Tomas, Manila, Philippines

Sandra Navarra is Professor and Head of Rheumatology at University of Santo Tomas Hospital, Manila, Philippines. She served as Secretary-General, head of the Education Committee, chaired the special interest group on systemic lupus erythematosus (SLE) of the Asia Pacific League of Associations for Rheumatology (APLAR), and was past-President of the Philippine Rheumatology Association.

Professor Navarra co-founded the Arthritis Care and Research Foundation of the Philippines, where she was Scientific Programs Director, and the Lupus Foundation of the Philippines where she has served as Medical Adviser. Currently President and CEO of the Rheumatology Educational Trust Foundation Inc. (RETFI), she is the prime mover of the Lupus Inspired Advocacy (LUISA) Project for lupus education and research, and the People Empowerment for Arthritis and Lupus (PEARL) Movement for lay education and medical assistance programs. Professor Navarra is a member of the Lupus Academy Steering Committee, and a founding and executive board member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).

Professor Navarra is an experienced clinical trials investigator and has published widely in the field of lupus and other rheumatic diseases. She is a well-known lecturer in a broad range of topics in Rheumatology and has received several university and national awards for her contributions to education and research. She has organized several national and regional educational meetings including the Ten Topics in Rheumatology – Asia (November 2009), first Asian Lupus Summit (November 2012), Asian Lupus Summit by Lupus Academy (March 2014), Lupus Nephritis Forum (July 2015), Lupus Academy Roadshow Meetings (May 2016, November 2017, May 2018), Musculoskeletal Imaging for Clinicians and Lupus for the Internist (May 2019) – all held in the Philippines.

Professor Navarra is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

Grants/Research: *Astellas*
Consultant/Advisor: *Astellas*
Speakers' Bureau: *Astellas*



Professor Bernardo Pons-Estel, MD
Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina

Bernardo Pons-Estel is Head of the Regional Center for Autoimmune and Rheumatic Diseases (CREAR), and the Cardiovascular Institute of Rosario (ICR), Argentina. He received his medical degree from the National University of Rosario and went on to train in rheumatology, first in Argentina (Rosario) and thereafter the USA, where he was a fellow at New York University (Bellevue Hospital and the Irvington House Institute, New York) and at the University of Missouri Cancer Research Center, Columbia.

Professor Pons-Estel is the main coordinator for the Latin American Group for the Study of Systemic Lupus Erythematosus (GLADEL), the Genomic Study of Latin-American Patients with SLE (GLA-GENLES) and the Latin American Group for the Study of Rheumatic Diseases in Indigenous People (GLADERPO). He is past-President of the Argentinean Rheumatology Society (2011–2013). In 2013, he chaired the 10th International Congress on SLE, which took place under GLADEL sponsorship in Buenos Aires, Argentina and in 2018 he chaired the Pan-American League of Rheumatology Associations (PANLAR) Congress in Buenos Aires.

Professor Pons-Estel is a council member of the Science and Educational Committee of the Pan-American League of Association for Rheumatology (PANLAR). He is also an active member of the Systemic Lupus International Collaborating Clinics (SLICC), member of the Lupus Academy Steering Committee and an International Member of the ACR. Recently, a collaboration between GLADEL and PANLAR materialised, the aim being the development of guidelines for the management of SLE patients from the Latin American subcontinent; Bernardo is an integral part of this collaboration.

Professor Pons Estel is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

None

Biographies



Dr Chiara Tani, MD, PhD
University of Pisa, Italy

Chiara Tani is Consultant Rheumatologist at the Rheumatology Unit, University of Pisa, Italy. She received her medical degree and qualification in rheumatology from the University of Pisa. In 2012 she received her PhD from the University of Pisa with a basic science project on mesenchymal stromal cells as a potential treatment for systemic lupus erythematosus (SLE).

The Unit in which Dr Tani works is a tertiary referral centre for the diagnosis and management of patients affected with systemic autoimmune diseases and coordinating centre of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET). She is in charge of the pregnancy clinic of the unit with a recognised expertise in the management and follow-up of pregnant patients with systemic rheumatic diseases.

Dr Tani has authored over 100 iSi publications and the major topics include descriptions of clinical manifestations, prognostic risk factors, therapeutic interventions and pregnancy in SLE and other connective tissue diseases. Basic science publications were focused on pre-clinical models of SLE and mesenchymal stromal cells. She is the junior author of the chapter on undifferentiated connective tissue disease, mixed connective tissue disease and overlap syndromes for the last two editions of the EULAR textbook for rheumatic diseases.

Dr Tani has been a member of the Italian Society of Rheumatology (SIR) since 2011 and of the EMEUNET since 2012. From 2010 to 2016 Chiara Tani was Assistant Editor for the journal *Clinical and Experimental Rheumatology*.

Financial Disclosures

None



Professor Angela Tincani

ASST-Spedali Civili di Brescia, Italy

Angela Tincani is Senior Consultant at Rheumatology and Clinical Immunology Unit at the “ASST-Spedali Civili di Brescia”, Italy and Professor at Rheumatology Specialization, University of Brescia. She is also visiting professor at Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. Previously Head of the Rheumatology and Clinical Immunology Unit at the “ASST-Spedali Civili di Brescia”, Italy.

Professor Tincani received her medical degree and qualification in Clinical Immunology and Rheumatology from the University of Milan. She was a Council Member of the Italian Society of Rheumatology (SIR) from 2015–2018, Member of the EULAR Scientific Committee (2017–2019), and invited by the American College of Rheumatology to serve as an abstract category Co-Chair of the “Reproductive issues in Rheumatic disorders” (2017–2020).

Professor Tincani has been committee member or chair of many international conferences on SLE, Antiphospholipid Antibodies, Autoimmunity, Pregnancy in Rheumatic Diseases. She was involved in the EULAR task forces as an “expert” for the development of recommendation:

- “EULAR Recommendations for Management of SLE and Clinical End-Points in Lupus Trials”
- “Physical Examination and its Relationship to Functional Anatomy in Rheumatology”
- “Development of Recommendations for Monitoring Systemic Lupus Erythematosus (SLE) Patients in Clinical Practice and in Observational Studies”
- “Points to consider for use of anti-rheumatic drugs before pregnancy and during pregnancy and lactation”

In addition, she proposed and conducted as Co-Chair the EULAR task forces on:

- “Development and validation of a new patient reported outcome questionnaire to estimate vitamin D status and its correlation with quality of life, disease activity and disability in rheumatoid arthritis patients in Europe”,
- “Recommendations for the management of family planning, assisted reproduction, gestation, delivery and menopause in patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome”,
- “Recommendations for the management of adult Antiphospholipid Syndrome”. Professor Tincani will chair the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases which will be held in Stresa (Italy) 6-8 May 2021.

Professor Tincani is on the Editorial Board of several journals including: *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews* and *Reumatismo* (the official journal of Italian Society of Rheumatology). She has authored more than 300 publications on the management of patients with systemic autoimmune diseases, regarding both diagnosis (including validation and use of novel biomarkers) and treatment (including new clinical trials) of: systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, systemic vasculitis, inflammatory myositis and inflammatory arthritis. Several publications focus on reproductive related issues such as management of patients with rheumatic diseases during pregnancy, use of anti-rheumatic drugs during pregnancy and lactation, evaluation of different autoimmune diseases and autoantibodies as risk factors for poor gestational outcome.

Professor Tincani has a recognised experience in the clinical management of patients with autoimmune rheumatic diseases. The Rheumatology and Clinical Immunology of Brescia is a tertiary referral centre especially for systemic lupus erythematosus, antiphospholipid syndrome and systemic sclerosis. In addition, since 1990 is the base of the multidisciplinary Pregnancy Clinic in Rheumatic Diseases, in close collaboration with Obstetrics & Gynecology Department and Neonatal Intensive Care Unit of the ASST-Spedali Civili/University of Brescia.


As Professor of Rheumatology of Brescia University, Professor Tincani trained many students and fellows.

Financial Disclosures

Consultant/Advisor: Janssen; Novartis; UCB

Speakers' Bureau: GSK; Janssen; Novartis; Pfizer

Biographies



Professor Urowitz is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Financial Disclosures

None

Professor Murray Urowitz, MD

University of Toronto, Canada

Murray Urowitz is Professor of Medicine at the University of Toronto and Director of the Centre for Prognosis Studies in the Rheumatic Diseases and the Lupus Clinic at the Toronto Western Hospital.

Professor Urowitz was a founding member of the Systemic Lupus International Collaborating Clinics (SLICC) group and currently directs the SLICC Registry for Atherosclerosis. In 1995 he was the recipient of the Distinguished Rheumatologist Award of the Canadian Rheumatology Association and in 2009 he was recipient of the Evelyn V. HESS Award for outstanding contributions to lupus research, awarded by the Lupus Foundation of America. He was the recipient of the Queen Elizabeth Diamond Jubilee Medal for longstanding contributions to lupus research work in the field of rheumatology in 2015. In 2017 he was awarded the Distinguished Clinical Investigator Award for exceptional contributions to the field of rheumatology by the American College of Rheumatology. In May 2019 was the recipient of the University of Toronto Dean's Alumni Lifetime Achievement Award for Global Impact.

Professor Urowitz has published over 400 peer-reviewed papers and 44 book chapters. He has supervised the training of over 140 fellows in rheumatology especially in systemic lupus erythematosus.



Professor Ronald van Vollenhoven, MD, PhD

Amsterdam University Medical Centers, and Amsterdam Rheumatology & Immunology Center, Netherlands

Professor Ronald van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology and Immunology Center ARC in Amsterdam, the Netherlands.

Professor Ronald van Vollenhoven received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by residency (specialty training) in Internal Medicine at the State University of New York at Stony Brook, and a fellowship in Rheumatology at Stanford University in Palo Alto following which he received American Board of Internal Medicine certification in both Internal Medicine and Rheumatology.

From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 he moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; in 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute.

In January 2016 Professor Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at both the AMC and VUMC hospitals, which in 2018 merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC. He is also the Director of the Amsterdam Rheumatology and Immunology Center ARC, and Chair of the Rheumatology Research Council at Reade in Amsterdam, all located in Amsterdam, the Netherlands. Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database) for this purpose, which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials. He has published over 300 original papers (H-index: 65), book chapters and reviews, and is associate-editor of Dubois' Lupus Erythematosus (Elsevier, 2014), editor of the textbook Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015), author of the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-author, with Professor Laurent Arnaud, of the Handbook of Systemic Lupus Erythematosus (Springer, 2017). In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatological societies. He is the Editor-in-Chief of Lupus Science & Medicine, Member-elect of the EULAR Executive, past-Chair of the Swedish Rheumatology Society Professors' Council, co-founder of the IRBIS registry for biologics in SLE, the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives.

Professor van Vollenhoven is married and has two children. Outside his professional life he is an avid classical pianist.

Financial Disclosures

Grants/Research: BMS; GSK;

Lilly; UCB

Support for Educational programs (institutional grants): Pfizer; Roche

Consultant/Advisor: AbbVie; AstraZeneca; Biogen; Biotest; Celgene; Galapagos; Gilead; Janssen; Pfizer; Servier; UCB

Speaker, for which institutional and/or personal honoraria were received:

AbbVie; Galapagos; Janssen; Pfizer; UCB

Professor van Vollenhoven is a member of the Lupus Academy Steering Committee and as Chairman (2020) has been involved in the planning and development of the 9th Annual Meeting programme and materials.

Biographies



Financial Disclosures

Grants/Research: BMS; Pfizer

Consultant/Advisor: Jansen-Cilag; Roche; Sanofi; Novartis

Speakers' Bureau: Novartis; Pfizer; Sanofi

Professor Reinhard E. Voll, MD

University Medical Center, University of Freiburg, Germany

Reinhard Voll is Medical Director of the Division of Rheumatology and Clinical Immunology at the University Medical Center, University of Freiburg, Germany.

Professor Voll received his MD degree from the University Erlangen-Nürnberg, Germany. After completing his MD thesis, which was focused on regulatory proteins of HIV-1, he continued research as a postdoctoral fellow at the Max-Planck Research Groups for Rheumatology, University Hospital Erlangen. In 1996 he received a fellowship from the German Research Society (DFG) to investigate the transcription factor NF- κ B in lymphocytes in the laboratory of Dr. Sankar Ghosh, Section of Immunobiology, Yale University School of Medicine, USA. In 1999 he returned to the University Hospital Erlangen, Germany, to complete his clinical training in internal medicine (2004) and rheumatology (2006). From 2003 to 2009 he was Head of the "IZKF Young Investigator Research Group N2" at the Interdisciplinary Center for Clinical Research Erlangen. He served as senior attending physician at the Department of Rheumatology, University Hospital Erlangen for 6 years until he became Chair of Rheumatology and Clinical Immunology at the University Medical Center Freiburg.

Professor Voll's main research interests are the immunopathogenesis of systemic lupus erythematosus, plasma cell biology and plasma cell-targeted therapies. Other projects in his laboratory investigate cell type-selective interference with intracellular signaling pathways using the sneaking ligand approach.

Professor Voll has published more than 130 papers in peer reviewed journals including *Nature* and *Nature Medicine*.



Financial Disclosures

None

Professor Alexandre Voskuyl, MD, PhD

Amsterdam University Medical Centers, Netherlands

Alexandre Voskuyl is Rheumatologist and Professor of Rheumatology at the Department of Rheumatology and Clinical immunology of the Amsterdam UMC, VUMC, Amsterdam, Netherlands.

Professor Voskuyl has special interest in systemic autoimmune disease, in particular systemic lupus erythematosus and systemic sclerosis. His scientific work is focused on clinical outcome and biomarkers in systemic autoimmune diseases. He is member of the international taskforce definition of remission in SLE (DORIS), and since 2016 he has also been a member of SLICC group. He has participated in several international recommendations, including the 2019 EULAR/ERA-EDTA recommendation on the management of lupus nephritis.

Professor Voskuyl has been president and member of several national taskforces on SLE, systemic sclerosis, and small vessel vasculitis. He has authored over 240 ISI publications. He has longstanding clinical experience in the management of systemic autoimmune diseases and his centre is a national centre of excellence for systemic autoimmune diseases.




Dr Margherita Zen, MD, PhD
University of Padova, Italy

Dr Margherita Zen works as university researcher at the Unit of Connective Tissue Disease and Rare Rheumatic Diseases, Division of Rheumatology, Department of Medicine, University of Padua, Italy.

Dr Zen received her medical degree and qualification in Rheumatology from the University of Padua in 2009 and 2016, respectively, and she recently obtained her doctorate in Experimental and Clinical Medicine from the same University. For her researches, she was rewarded with prizes and scholarships from national institutions. She participated as invited speaker and abstract presenter in several international conferences. She has authored over 60 ISI publications on SLE and other connective tissue diseases, which include clinical studies describing disease outcomes, prognostic risk factors and therapeutic interventions. In addition, she has authored and co-authored over 200 abstracts for national and international conferences.

Financial Disclosures
None

Dr Zen works in a tertiary referral rheumatology centre in Northeast Italy, and she has experience in the diagnosis and clinical management of patients with connective tissue diseases. She participated as sub-investigator and principal investigator in phase II and phase III clinical trials on new targeted therapies for SLE. She is member of the Italian Society of Rheumatology, SLEuro, and ERN ReCONNECT.



About the Lupus Academy

Mission

The Lupus Academy is a not-for-profit, long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

Meeting Organisation

The 9th Annual Meeting of the Lupus Academy has been developed under the control of the meeting Chairs: Professor Andrea Doria (Italy) and Professor Ronald van Vollenhoven (Netherlands), on behalf of the Steering Committee of the Lupus Academy, and with the support of the planning staff at Lupus Academy. It has been developed in Joint Providership with Siyemi Learning, an ACCME-accredited provider for CME compliance and certification. No other individuals or organisations have had any influence over the content of this meeting.

Other Educational Activities

The Lupus Academy runs an Annual Meeting and several regional Roadshow Meetings each year. It also has an extensive library of presentations that is available to registered members, currently free of charge. The Lupus Academy is also developing a series of eLearning activities to support its educational goals. From 2019 Lupus Academy has been proud to be the provider of the eLearning course on SLE for the European League Against Rheumatism (EULAR).

More information about all Lupus Academy educational activities can be found at lupus-academy.org.

Further Information

The Lupus Academy is a not-for-profit educational foundation with its office in the Netherlands, RSIN 851342097.

Lupus Academy Foundation
Maasdijk 409
4264 AS Veen
The Netherlands

Supporters



 **LupusAcademy**
Communicate. Educate. Treat.

Financial Supporters

INDEPENDENT EDUCATIONAL GRANTS


GSK
BMS

SILVER SPONSOR
Janssen

BRONZE SPONSOR
Amgen, AstraZeneca, Aurinia, Boehringer Ingelheim, Galapagos, Lilly, Roche, UCB

ACADEMY PARTNER
Biogen

In-kind Supporters



Financial and in-kind support is only accepted on a strictly “hands-off” basis, where the supporting companies do not have any control or influence over the planning, content, speaker selection or execution of educational activities. Support is received as educational grants, sponsorship, donations or in-kind, and where used, clearly identified.

